K vs. +70K consensus and +48K prior (revised from +50K), according to data released by the Bureau of Labor Statistics on Wednesday.

Credo raised its FY revenue outlook by 20% to $406M, signaling strong hyperscaler demand. Click here to find out why CRDO is ...

NNN REIT introduced full-year guidance roughly in line with the consensus estimate after turning in solid beats on Q4 ...

Embotelladora Andina (AKO.B, AKO.A) delivered solid sales growth in CLP, but volume and margin trends were mixed across regions.

Universal Corporation (UVV) experienced a sharp post-earnings stock drop after missing analyst estimates on both revenue and ...

Precigen (PGEN) surged dramatically since the FDA approval of PAPZIMEOS, its first-in-class therapy for Recurrent Respiratory Papillomatosis (RRP).

British American Tobacco has rebounded sharply, driven by profitable growth in its modern product portfolio and improving ...

VONV ETF review: underperformance, value traps, sector tilts (financials/industrials) and weaker Sharpe raise concerns.

BP is upgraded to Buy, driven by a strategic pivot to value, high-margin hydrocarbon production, and disciplined capital allocation. Click for more on BP stock.

CoreWeave, Inc. offers a compelling risk/reward setup ahead of Q4 earnings, with significant upside potential despite recent ...

Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read ...

BP suspended its buyback program to prioritize deleveraging, targeting net debt reduction from $22B to $14–$18B by 2027. Click to read why BP is a Strong Sell.